Thursday Jul 17
MediGene AG's Drug Veregen Launched In Canada
Martinsried/Munich, July 17, 2014 . Medigene AG announces the launch of its drug VeregenA for the treatment of genital warts in Canada through the marketing partner Paladin Labs Inc. .
Endo's Paladin Labs Reports Canadian Introduction Of Veregen
Paladin Labs Inc., a subsidiary of Endo International plc and a leading Canadian specialty pharmaceutical company, today announced the launch of VeregenA Ointment, 10%, a topical treatment for external genital and perianal warts in immunocompetent patients aged 18 years and over.
Endo buys generics maker DAVA for $575M
The corporate shifting by Endo International P.L.C. continued Tuesday as the drugmaker said it will pay $575 million for privately-held DAVA Pharmaceuticals in hopes of quickly generating more revenue.